India has a significant opportunity to lead in the transition from generics to biologics by focusing on building capacity for next-generation biologic modalities and securing access to essential inputs. Biologics such as cell and gene therapies, monoclonal antibodies, antibody-drug conjugates, and nucleic acid-based treatments rely on a complex array of components like expression vectors, engineered […]